Craniometrix vs Pfizer

Side-by-side comparison of AI visibility scores, market position, and capabilities

Pfizer leads in AI visibility (93 vs 36)
Craniometrix logo

Craniometrix

EmergingHealthcare

General

SF dementia care coordination platform with Johns Hopkins MIND at Home partnership; YC $6.5M with $1.9M revenue connecting patients and caregivers through virtual care navigation for Alzheimer's management.

AI VisibilityBeta
Overall Score
D36
Category Rank
#503 of 596
AI Consensus
85%
Trend
stable
Per Platform
ChatGPT
41
Perplexity
36
Gemini
36

About

Craniometrix is a San Francisco-based digital health company providing virtual dementia care coordination — connecting dementia patients, family caregivers, and healthcare providers through a telemedicine platform that delivers cognitive assessment, care planning, caregiver education, and ongoing care management for Alzheimer's and related dementia conditions. Founded by CEO Nikhil Patel and backed by Y Combinator with $6-6.5 million raised from Y Combinator, Quiet Capital, and Defy.vc, Craniometrix generated $1.9 million in revenue in 2024 and partners with the Johns Hopkins MIND at Home program — a validated community-based dementia care model developed by Johns Hopkins University School of Medicine.

Full profile
Pfizer logo

Pfizer

LeaderHealthcare Tech

Enterprise

Global biopharma with $63.6B FY2024 revenue; $43B Seagen ADC acquisition rebuilds post-COVID pipeline; patent cliff 2026-2028 for Eliquis; activist Starboard Value pushing restructuring.

AI VisibilityBeta
Overall Score
A93
Category Rank
#1 of 596
AI Consensus
80%
Trend
stable
Per Platform
ChatGPT
94
Perplexity
89
Gemini
94

About

Pfizer is one of the world's largest biopharmaceutical companies, founded in 1849 by cousins Charles Pfizer and Charles Erhart in Brooklyn, New York, and now headquartered in New York City. The company trades on NYSE (PFE) and reported $63.6 billion in total revenues for FY2024, normalizing from pandemic highs of $100 billion-plus in 2021-2022 driven by Comirnaty COVID-19 vaccine revenues with BioNTech and Paxlovid COVID antiviral sales. CEO Albert Bourla has led a strategic pivot to reset the company's long-term growth profile, anchored by the landmark $43 billion acquisition of Seagen in December 2023, adding a world-class antibody-drug conjugate (ADC) oncology pipeline including Padcev, Tukysa, Adcetris, and Tivdak.

Full profile

AI Visibility Head-to-Head

36
Overall Score
93
#503
Category Rank
#1
85
AI Consensus
80
stable
Trend
stable
41
ChatGPT
94
36
Perplexity
89
36
Gemini
94
41
Claude
92
39
Grok
98

Key Details

Category
General
Enterprise
Tier
Emerging
Leader
Entity Type
brand
company

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.